nPOD Webinars

View past and upcoming webinars hosted by nPOD investigators.

Upcoming Webinars

nPOD Investigators, Group Presentation nPOD, University of Florida October/2017 nPOD Case Deep Dive: #6243

 

DATE: Tuesday, October 24th, 2017

WEBINAR INFO: 
Click here to join WebEx Meeting
Meeting Number (access code): 739 507 897
Meeting password: diabetes
Call-in toll number (US/Canada): 1-650-479-3208
Global Call-in Numbers
Can’t join the meeting?

TIME: 12:00pm – 1:00pm EST

SPEAKERS: nPOD Investigators, group discussion led by Alberto Puglese, MD

Click here to download the calendar event and WebEx link.

The nPOD “Deep Dive” Case Study webinar series aims to unite the efforts, expertise, and resources of various Investigators within the nPOD cohort in order to paint a uniquely detailed and comprehensive picture of the development of type 1 diabetes in individual donors of interest. By “comparing notes” in this way, we believe this webinar series will provide a unique opportunity for a deep analysis of individual nPOD donors, based on the synthesis of each presenter’s area of expertise. Not only will this series allow each Investigator to add their “part” to the “whole”, it is also our hope that each nPOD Investigator will be able to walk away from the webinar with new insights from other studies that will inform their research going forward.

This series will begin with the well-studied nPOD Case #6243. This donor was a 13-year-old male who had T1D for 5 years, was mIAA+, and as a “typical” T1D case with both insulitis and insulin-positive islets, will be a fantastic starting place for such an in-depth and collaborative analysis.

All nPOD Investigators are invited to present 1-3 slides of data they may have on Case #6243.  If you are unable to attend the webinar in person, we ask that you would still consider sending any data you have on this case to be presented on your behalf. Everyone is invited to attend the webinar, even if your research has not examined this particular case! A recording of the webinar will be made available for those unable to attend.

If you are able to provide data for nPOD Case #6243, please email slides to Amanda Myers by Friday, October 13th.

Past Webinars

Sally Kent, PhD & Maki Nakayama, MD, PhD University of Massachusetts Medical School; University of Colorado January/2017 Islet-Infiltrating T Cell Repertoire: Two Studies

Kent - Nakayama
DATE:
Wednesday, January 11th, 2017

SPEAKERS: Sally Kent, PhD
University of Massachusetts Medical School

Maki Nakayama, MD, PhD
University of Colorado

Click here to view a recording of the webinar.

Broad Repertoire of Autoreactive T Cells from the Islets of Donors with Type 1 Diabetes:
In this webinar, we will be discussing our recent study on the analyses of live, autoreactive CD4 and CD8 T cells derived directly from the islets of donors with type 1 diabetes (Babon et. al., Nature Medicine, 2016, PMID: 27798614). We will be discussing the islet samples, handling of the islets, isolation and growth of T cells from the islets, and analyses of their autoreactivity and function to known islet peptide targets and to modified peptides. We will also discuss current and future studies in these ongoing analyses.

Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes:
Type 1 diabetes results from chronic autoimmune destruction of insulin-producing beta cells within pancreatic islets. While insulin is a critical self-antigen in animal models of autoimmune diabetes, due to extremely limited access to pancreas samples, little is known about human antigenic targets for islet-infiltrating T-cells. In this webinar, we will show that proinsulin peptides are targeted by islet-infiltrating T-cells from type 1 diabetes patients. We identified hundreds of T-cells from inflamed pancreatic islets of three young type 1 diabetes organ donors with a short disease duration with high risk HLA genes using a direct T-cell receptor (TCR) sequencing approach without long-term cell culture. Among 85 selected CD4 TCRs tested for reactivity to preproinsulin peptides presented by diabetes-susceptible HLA-DQ and -DR molecules, one T-cell recognized C-peptide amino acids 19-35, and two clones from separate donors responded to insulin B chain amino acids 9-23 (B:9-23) which is known to be a critical self-antigen driving disease progress in animal models of autoimmune diabetes. These B:9-23-specific T-cells from islets responded to whole proinsulin and islets, while previously identified B:9-23 responsive clones from peripheral blood did not, highlighting the importance of proinsulin-specific T-cells in the islet microenvironment.

Maria Beery, MS & Irina Kusmartseva, PhD nPOD, University of Florida November/2016 Maximizing Your nPOD Sample Request: Using Online Pathology and DataShare to Select the Right Cases for Your Study


DATE:
Wednesday, November 30th, 2016

SPEAKERS: Maria Beery, MS
nPOD Senior Biological Scientist

Irina Kusmartseva
nPOD Organ Processing and Pathology Core (OPPC) Director

Click here to view a recording of the webinar. Download PowerPoint presentation.

As any veteran nPOD investigator knows, every donor case is different.  While it is tempting to order based on donor classification alone, we encourage our investigators to be highly selective when requesting material for their studies and to take into consideration both the donor’s clinical history and histopathology report.  All nPOD case information is compiled in two distinct databases, Online Pathology and DataShare.

Our Online Pathology database, hosted by Aperio eSlide Manager, displays basic donor demographics alongside high quality scanned images of pancreas, spleen, lymph node, and duodenum sections.  While not every sample type will be available for every case, several available blocks are screened by H&E and stained for insulin, glucagon, CD3, and other pertinent markers.  In the event that insulitis is found in Type 1 cases, all available pancreas blocks are screened.  Viewing images in Online Pathology gives you the ability to make informed decisions about which sample blocks are most relevant to your study.

Our second database, DataShare, supplies an abundance of clinical data, shared nPOD investigator data, and access to our sample request system.  Using DataShare in conjunction with Online Pathology allows you to match cases of interest by age, gender, autoantibody status, BMI, and a host of other variables while viewing images from available samples at the same time.  In this webinar, the nPOD OPPC team will provide guidance and general tips for navigating both databases and ordering the samples that best suit your needs.

Laura Jacobsen, MD University of Florida July/2016 Venue for Highlighting Unique nPOD Cases: Clinical Images in Diabetes

laura
DATE:
Tuesday, July 26th, 2016

SPEAKER: Laura Jacobsen, MD
University of Florida

Click here to view a recording of the webinar.

The nPOD database offers a wealth of knowledge; consolidating a large series of cases and slides into a collective that provides valuable data towards common features for the disorder’s pathogenesis.  However, extensive information also exists in individual cases, a feature that can offer unique insights into disease pathophysiology at a personalized level.   These latter findings can be presented in a brief, case-based report focused around images, specifically using nPOD histological images.

The Clinical Images in Diabetes section within the journal Diabetes Care represents an exciting, new (July, 2016) forum for conveying case-reports. This section, developed in part with guidance from nPOD, is almost tailor-made for reporting nPOD cases.  Indeed, two nPOD cases have already been accepted for publication and others are being considered.   First, was nPOD case 6196, looking at a clinical case of type 1 diabetes (T1D) with positive GAD autoantibodies, but contradictory histology (numerous insulin-positive islets and amyloid present) (Diabetes Care 2016 Jul; 39(7): 1292-1294).  The second report, nPOD case 6263, is in press and focuses again on contradictory findings between clinical/laboratory review and histological features.  This case was also analyzed further in the setting of ethnicity as well as genetic findings of yet to be determined significance.  These cases were chosen after our team, made up of pediatric endocrinologists and pathologists, reviewed the donor charts and available laboratory data in conjunction with the histological images and there were unexpected findings or unique characteristics.  These cases, their reviewer critiques and ways to get started will be presented, as well as the criteria set forth by Diabetes Care for this Clinical Images in Diabetes section, to encourage nPOD investigators to, in like form, present additional interesting cases from the nPOD collection. This, for the purpose of furthering the notion of disease heterogeneity in T1D as well as to provide novel insights towards the various pathogenic mechanisms leading to diabetes.

REFERENCES: 

Alex Marson, MD, PhD University of California, San Francisco April/2016 Genetic and Epigenetic Fine-Mapping of Causal Type 1 Diabetes Risk Variants

photo

DATE: Tuesday, April 26th, 2016

SPEAKER: Alex Marson, MD, PhD, University of California, San Francisco

Click here to view a recording of the webinar.

Type 1 diabetes (T1D) has been the subject of intensive genetic investigations, including genome-wide association studies (GWAS) that have collectively identified over 40 risk loci in the genome. Our knowledge of the genetic code provides a powerful framework to understand the deleterious effects of variants that alter protein sequence. However, almost 90% of common variants associated with T1D and other autoimmune diseases fall outside of genes, in non-coding, regulatory regions of the genome—regions previously described as ‘junk DNA.’ We still do not know how DNA variation throughout the genome, especially in non-coding regions, affects cellular pathways and contributes to T1D. We need to develop sophisticated analytic and experimental tools to delve deeper into the function of these non-coding genome elements.

We recently leveraged the latest high-density genotyping data on patients with autoimmune diseases to develop a new algorithm to fine-map the specific variants most likely to cause increased risk of disease. To interpret the biological processes affected by candidate non-coding variants, we generated a large epigenetic resource of cis­-regulatory maps of specialized human cells. Comparing SNP locations with chromatin maps for 56 cell types revealed the cell type-specificities of cis-regulatory elements that coincide with fine-mapped risk for T1D and other autoimmune diseases, thus predicting pathogenic cell types. While the primary signature of T1D risk variants is in immune cell enhancers, we also found enrichment in pancreatic islet   enhancers.

Moving forward, we will collaborate with nPOD to test the in vivo effects of the variants on chromatin state and gene expression in a population-based study of genotyped T cell samples sorted directly from the pancreatic lymph nodes of human organ donors with and without T1D. Understanding how causal non-coding T1D risk variants disrupt key gene programs controlling cell function will provide critical information linking genetic variation to cellular pathways. This knowledge could accelerate development of targeted therapeutic approaches.

Erik Yusko, PhD & Todd Brusko, PhD Adaptive Biotechnologies; University of Florida December/2015 Immunosequencing: Generating a Potential New Class of Diagnostics


DATE
: Tuesday, December 15th, 2015

SPEAKER: Erik Yusko, PhD, Adaptive Biotechnologies
Todd Brusko, PhD, University of Florida

Click here to view a recording of the webinar.

The cellular and humoral adaptive immune system generates a remarkable breadth of diversity of antigen receptors by combinatorial shuffling of gene segments in somatic cells.  The diversity of possible receptors is large and until recently this diversity precluded the possibility of capturing the antigen receptor repertoires. We have developed a method for unbiased amplification of rearranged T-cell and B-cell receptor variable regions and the use of high throughput sequencing to capture millions of these sequences.  We have applied the technology to a variety of clinical problems including hematological malignancies, solid tumor immunology, and the immune response to pathogenic stimulation. The technology is used clinically in Adaptive Biotechnologies’ CLIA lab for diagnosis/patient stratification for leukemia and lymphoma, monitoring minimal residual disease, and measuring immune reconstitution after transplant. For application to solid tumors, infiltrating lymphocyte count and clonality are both predictive of response to immunotherapy and prognostic of clinical outcome with standard treatment.  Preliminary results from TCRB profiling of various tissues from nPOD donors will also be presented.

REFERENCES: